Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Non-Current Assets (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Non-Current Assets readings, the most recent being $717000.0 for Q1 2026.

  • Quarterly Non-Current Assets fell 49.08% to $717000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $717000.0 through Mar 2026, down 49.08% year-over-year, with the annual reading at $742000.0 for FY2025, 57.23% down from the prior year.
  • Non-Current Assets hit $717000.0 in Q1 2026 for DiaMedica Therapeutics, down from $742000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $20.8 million in Q2 2023 and bottomed at $85000.0 in Q2 2022.
  • Average Non-Current Assets over 5 years is $2.6 million, with a median of $742000.0 recorded in 2025.
  • The largest annual shift saw Non-Current Assets skyrocketed 24392.94% in 2023 before it crashed 91.46% in 2024.
  • DiaMedica Therapeutics' Non-Current Assets stood at $560000.0 in 2022, then fell by 13.39% to $485000.0 in 2023, then soared by 257.73% to $1.7 million in 2024, then crashed by 57.23% to $742000.0 in 2025, then decreased by 3.37% to $717000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Non-Current Assets are $717000.0 (Q1 2026), $742000.0 (Q4 2025), and $824000.0 (Q3 2025).